Publications by authors named "Sam H Whiting"

Claim this Profile
F
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler, Chan C Whiting, Sam H Whiting

Cancer Res Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Andrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, David B Zhen, James O Park, Sam H Whiting

Pancreas· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Sam H Whiting

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
James J Harding, Melinda Telli, Pamela Munster, Martin H Voss, Jeffrey R Infante, Sam H Whiting

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis